Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Trial Profile

Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2013

At a glance

  • Drugs Vidofludimus (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ENTRANCE
  • Most Recent Events

    • 09 May 2011 Final results presented at Digestive Disease Week (DDW-2011).
    • 09 May 2011 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2011 Results reported at the 6th ECCO IBD Conference in February 2011, according to a 4SC media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top